Prot# EGF100151: A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 and Capecitabine (Xeloda®) versus Capectiabine in Women with Refractory Advanced or Metastatic Breast Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date6/14/05 → 8/28/07

Funding

  • GlaxoSmithKline plc (EGF100151)